RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재후보 SCIE SCOPUS

      Current status of cervical cancer and HPV infection in Korea

      한글로보기

      https://www.riss.kr/link?id=A104748108

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      Cervical cancer is an important cause of cancer-related deaths in women in developing countries. In Korea, cervical
      cancer is the third leading cancer among females and is fifth highest in mortality. The persistent oncogenic human
      papillomavirus (HPV) infections are the greatest risk of developing cervical intraepithelial neoplasia and invasive
      cancer. The overall prevalence of HPV was 10.4% in Korea and strong risk factors for HPV infection included a young
      age at sexual debut. The National Cancer Screening Program, which includes cervical cancer screening, has the
      following principles: the main screening tool is the Papanicolaou test conducted by gynecologists, which targets all
      women age 30 and over, and which is done every 2 years. HPV DNA tests have not yet been permitted as a screening
      test for cervical cancer in Korea; however, these are conducted along with a Pap test for screening cervical cancer in
      the clinic. The use of prophylactic HPV vaccine has been accepted in Korea; The Korean Society of Gynecologic
      Oncology and Colposcopy’s recommendation for routine vaccination is for females aged 15-17 years with a catch-up
      vaccination recommended for females aged 18-26 years who have not been previously vaccinated. However, many
      people in Korea are not familiar with the HPV vaccine. Therefore, it is necessary to improve awareness for the disease
      and HPV vaccination and to establish the effective strategies to obtain funding for HPV vaccination. In the future,
      cervical cancer is expected to disappear throughout the world, including the Asia Pacific region, through a
      combination of vaccination and qualified screening programs for cervical cancer.
      번역하기

      Cervical cancer is an important cause of cancer-related deaths in women in developing countries. In Korea, cervical cancer is the third leading cancer among females and is fifth highest in mortality. The persistent oncogenic human papillomavirus (HPV)...

      Cervical cancer is an important cause of cancer-related deaths in women in developing countries. In Korea, cervical
      cancer is the third leading cancer among females and is fifth highest in mortality. The persistent oncogenic human
      papillomavirus (HPV) infections are the greatest risk of developing cervical intraepithelial neoplasia and invasive
      cancer. The overall prevalence of HPV was 10.4% in Korea and strong risk factors for HPV infection included a young
      age at sexual debut. The National Cancer Screening Program, which includes cervical cancer screening, has the
      following principles: the main screening tool is the Papanicolaou test conducted by gynecologists, which targets all
      women age 30 and over, and which is done every 2 years. HPV DNA tests have not yet been permitted as a screening
      test for cervical cancer in Korea; however, these are conducted along with a Pap test for screening cervical cancer in
      the clinic. The use of prophylactic HPV vaccine has been accepted in Korea; The Korean Society of Gynecologic
      Oncology and Colposcopy’s recommendation for routine vaccination is for females aged 15-17 years with a catch-up
      vaccination recommended for females aged 18-26 years who have not been previously vaccinated. However, many
      people in Korea are not familiar with the HPV vaccine. Therefore, it is necessary to improve awareness for the disease
      and HPV vaccination and to establish the effective strategies to obtain funding for HPV vaccination. In the future,
      cervical cancer is expected to disappear throughout the world, including the Asia Pacific region, through a
      combination of vaccination and qualified screening programs for cervical cancer.

      더보기

      다국어 초록 (Multilingual Abstract)

      Cervical cancer is an important cause of cancer-related deaths in women in developing countries. In Korea, cervical
      cancer is the third leading cancer among females and is fifth highest in mortality. The persistent oncogenic human
      papillomavirus (HPV) infections are the greatest risk of developing cervical intraepithelial neoplasia and invasive
      cancer. The overall prevalence of HPV was 10.4% in Korea and strong risk factors for HPV infection included a young
      age at sexual debut. The National Cancer Screening Program, which includes cervical cancer screening, has the
      following principles: the main screening tool is the Papanicolaou test conducted by gynecologists, which targets all
      women age 30 and over, and which is done every 2 years. HPV DNA tests have not yet been permitted as a screening
      test for cervical cancer in Korea; however, these are conducted along with a Pap test for screening cervical cancer in
      the clinic. The use of prophylactic HPV vaccine has been accepted in Korea; The Korean Society of Gynecologic
      Oncology and Colposcopy’s recommendation for routine vaccination is for females aged 15-17 years with a catch-up
      vaccination recommended for females aged 18-26 years who have not been previously vaccinated. However, many
      people in Korea are not familiar with the HPV vaccine. Therefore, it is necessary to improve awareness for the disease
      and HPV vaccination and to establish the effective strategies to obtain funding for HPV vaccination. In the future,
      cervical cancer is expected to disappear throughout the world, including the Asia Pacific region, through a
      combination of vaccination and qualified screening programs for cervical cancer.
      번역하기

      Cervical cancer is an important cause of cancer-related deaths in women in developing countries. In Korea, cervical cancer is the third leading cancer among females and is fifth highest in mortality. The persistent oncogenic human papillomavirus (HP...

      Cervical cancer is an important cause of cancer-related deaths in women in developing countries. In Korea, cervical
      cancer is the third leading cancer among females and is fifth highest in mortality. The persistent oncogenic human
      papillomavirus (HPV) infections are the greatest risk of developing cervical intraepithelial neoplasia and invasive
      cancer. The overall prevalence of HPV was 10.4% in Korea and strong risk factors for HPV infection included a young
      age at sexual debut. The National Cancer Screening Program, which includes cervical cancer screening, has the
      following principles: the main screening tool is the Papanicolaou test conducted by gynecologists, which targets all
      women age 30 and over, and which is done every 2 years. HPV DNA tests have not yet been permitted as a screening
      test for cervical cancer in Korea; however, these are conducted along with a Pap test for screening cervical cancer in
      the clinic. The use of prophylactic HPV vaccine has been accepted in Korea; The Korean Society of Gynecologic
      Oncology and Colposcopy’s recommendation for routine vaccination is for females aged 15-17 years with a catch-up
      vaccination recommended for females aged 18-26 years who have not been previously vaccinated. However, many
      people in Korea are not familiar with the HPV vaccine. Therefore, it is necessary to improve awareness for the disease
      and HPV vaccination and to establish the effective strategies to obtain funding for HPV vaccination. In the future,
      cervical cancer is expected to disappear throughout the world, including the Asia Pacific region, through a
      combination of vaccination and qualified screening programs for cervical cancer.

      더보기

      참고문헌 (Reference)

      1 김승조, "한국형 자궁경부 촬영진(New Cervicography), 세포검사 그리고 HPV-DNA 검사를 이용한 새로운 자궁경부암 검진 모델(Model) 개발" 대한산부인과학회 44 (44): 911-937, 2001

      2 김용범, "한국여성의 자궁경부암에서 인유두종바이러스의 감염 양상" 대한산부인과학회 46 (46): 789-794, 2003

      3 이제훈, "자궁경부암 조직을 이용한유전자 칩 인유두종바이러스 검사" 대한산부인과학회 49 (49): 858-865, 2006

      4 위정하, "자궁 경부 전암 병변 및 자궁 경부암 환자에서의 HPV 감염 양상 및다중감염의 분포" 대한부인종양콜포스코피학회 17 (17): 39-46, 2006

      5 Pollack AE, "WHO/UNFPA Working Group on Sexual and Reproductive Health and HPV Vaccines. Ensuring access to HPV vaccines through integrated services: a reproductive health perspective" 85 : 57-63, 2007

      6 Shin HR, "Trends in cervical cancer mortality in Korea 1993-2002: corrected mortality using national death certification data and national cancer incidence data" 122 : 393-397, 2008

      7 Lacey CJ, "Therapy for genital human papillomavirus-related disease" 32 (32): S82-S90, 2005

      8 The Ministry of Health and Welfare, "The third Korean national health and nutrition examination survey" Korea Center for Disease Control 2005

      9 The Ministry of Health and Welfare, "The second Korean national health and nutrition examination survey" Korea Center for Disease Control and Prevention 2001

      10 The Ministry of Health and Welfare, "The first Korean national health and nutrition examination survey" Korea Center for Disease Control 1998

      1 김승조, "한국형 자궁경부 촬영진(New Cervicography), 세포검사 그리고 HPV-DNA 검사를 이용한 새로운 자궁경부암 검진 모델(Model) 개발" 대한산부인과학회 44 (44): 911-937, 2001

      2 김용범, "한국여성의 자궁경부암에서 인유두종바이러스의 감염 양상" 대한산부인과학회 46 (46): 789-794, 2003

      3 이제훈, "자궁경부암 조직을 이용한유전자 칩 인유두종바이러스 검사" 대한산부인과학회 49 (49): 858-865, 2006

      4 위정하, "자궁 경부 전암 병변 및 자궁 경부암 환자에서의 HPV 감염 양상 및다중감염의 분포" 대한부인종양콜포스코피학회 17 (17): 39-46, 2006

      5 Pollack AE, "WHO/UNFPA Working Group on Sexual and Reproductive Health and HPV Vaccines. Ensuring access to HPV vaccines through integrated services: a reproductive health perspective" 85 : 57-63, 2007

      6 Shin HR, "Trends in cervical cancer mortality in Korea 1993-2002: corrected mortality using national death certification data and national cancer incidence data" 122 : 393-397, 2008

      7 Lacey CJ, "Therapy for genital human papillomavirus-related disease" 32 (32): S82-S90, 2005

      8 The Ministry of Health and Welfare, "The third Korean national health and nutrition examination survey" Korea Center for Disease Control 2005

      9 The Ministry of Health and Welfare, "The second Korean national health and nutrition examination survey" Korea Center for Disease Control and Prevention 2001

      10 The Ministry of Health and Welfare, "The first Korean national health and nutrition examination survey" Korea Center for Disease Control 1998

      11 Behbakht K, "Social and cultural barriers to Papanicolaou test screening in an urban population" 104 : 355-1361, 2004

      12 Korean Center for Disease Control and Prevention, "Second online survey for the health behavioral factors among adolescents in Korea in 2006" Korea Center for Disease Control and Prevention 2006

      13 Schneider A, "Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy" 89 : 529-534, 2000

      14 Cooper CP, "Report from the CDC. Pap test intervals used by physicians serving low-income women through the National Breast and Cervical Cancer Early Detection Program" 14 : 670-678, 2005

      15 Miller BA, "Racial/ethnic patterns of cancer in the United States 1988-1992" National Cancer Institute 1996

      16 Lowy DR, "Prophylactic human papillomavirus vaccines" 116 : 1167-1173, 2006

      17 Joo WD, "Prevalence of human papillomavirus infection in Korean women: risks of abnormal Pap smear and cervical neoplasia" 15 : 309-316, 2004

      18 Oh JK, "Prevalence of human papillomavirus and Chlamydia trachomatis infection among women attending cervical cancer screening in the Republic of Korea" 18 : 56-61, 2009

      19 An HJ, "Prevalence of human papillomavirus DNA in various histological subtypes of cervical adenocarcinoma: a populationbased study" 18 : 528-534, 2005

      20 Shin HR, "Prevalence of human papilloma virus infection in women in Busan, South Korea" 103 : 413-421, 2003

      21 Shin HR, "Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea" 190 : 468-476, 2004

      22 Hai-Rim Shin, "National Cancer Incidence for the Year 2002 in Korea" 대한암학회 39 (39): 139-149, 2007

      23 Bernstein SJ, "Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: a meta-analysis of prospective studies comparing cytologic diagnosis and sample adequacy" 185 : 308-317, 2001

      24 Shin JH, "Hybrid capture system HPV DNA test as a screening tool of cervical cancer" 12 : 31-38, 2001

      25 Lee HS, "Human papillomavirus genotyping using HPV DNA chip analysis in Korean women" 17 : 497-501, 2007

      26 Park TC, "Human papillomavirus genotyping by the DNA chip in the cervical neoplasia" 23 : 119-125, 2004

      27 Bae, Jeong-Hoon, "Human Papillomavirus (HPV) Type Distribution in Korean Women: A Meta-Analysis" 한국미생물·생명공학회 18 (18): 788-794, 2008

      28 Womack SD, "HPV-based cervical cancer screening in a population at high risk for HIV infection" 85 : 206-210, 2000

      29 Paavonen J, "HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomized controlled trial" 369 : 2161-2170, 2007

      30 Wright Jr TC, "HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer" 283 : 81-86, 2000

      31 Schiffman M, "HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica" 283 : 87-93, 2000

      32 Cho NH, "Genotyping of 22 human papillomavirus types by DNA chip in Korean women: comparison with cytologic diagnosis" 188 : 56-62, 2003

      33 Ault KA, "Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials" 369 : 1861-1868, 2007

      34 Garland SM, "Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators: quadrivalent vaccine against human papillomavirus to prevent anogenital diseases" 356 : 1928-1943, 2007

      35 Freeman HP, "Excess cervical cancer mortality: a marker for low access to health care in poor communities" National Cancer Institute 2005

      36 Munoz N, "Epidemiologic classification of human papillomavirus types associated with cervical cancer" 348 : 518-527, 2003

      37 Hwang T, "Detection and typing of human papillomavirus DNA by PCR using consensus primers in various cervical lesions of Korean women" 14 : 593-599, 1999

      38 Hwang TS, "Detection and typing of HPV genotypes in various cervical lesions by HPV oligonucleotide microarray" 90 : 51-56, 2003

      39 An HJ, "Correlation of cervical carcinoma and precancerous lesions with human papillomavirus (HPV) genotypes detected with the HPV DNA chip microarray method" 97 : 1672-1680, 2003

      40 De Villiers EM, "Classification of papillomaviruses" 324 : 17-27, 2004

      41 Park HK, "Cervical intraepithelial neoplasia and cervical cancer" 14 : 123-132, 2003

      42 Chung HH, "Cervical cancer incidence and survival in Korea: 1993-2002" 16 : 1833-1838, 2002

      43 Curado MP, "Cancer incidence in five continents. Volume IX" IARC 2007

      44 Parkin DM, "Cancer incidence in five continents, vol. VIII" IARC 2002

      45 Kyu-Won Jung, "Cancer Survival in Korea 1993-2002: A Population-Based Study" 대한의학회 22 (22): 5-10, 2007

      46 Blumenthal PD, "Adjunctive testing for cervical cancer in low resource settings with visual inspection, HPV, and the Pap smear" 72 : 47-53, 2001

      47 Nanda K, "Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review" 132 : 810-819, 2000

      48 Koo HW, "A case-control study on risk factors of uterine cervix cancer in Korea" 29 : 159-172, 1996

      더보기

      동일학술지(권/호) 다른 논문

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2023 평가예정 해외DB학술지평가 신청대상 (해외등재 학술지 평가)
      2020-01-01 평가 등재학술지 유지 (해외등재 학술지 평가) KCI등재
      2012-07-13 학회명변경 한글명 : 대한부인종양콜포스코피학회 -> 대한부인종양학회
      영문명 : Korean Society of Gynecologic Oncology and Colposcopy -> Korean Society of Gynecologic Oncology
      KCI등재
      2012-01-01 평가 등재학술지 선정 (등재후보2차) KCI등재
      2011-01-01 평가 등재후보 1차 PASS (등재후보1차) KCI등재후보
      2010-01-01 평가 등재후보학술지 유지 (등재후보2차) KCI등재후보
      2009-01-01 평가 등재후보 1차 PASS (등재후보1차) KCI등재후보
      2008-06-26 학술지명변경 한글명 : 부인종양 -> Journal of Gynecologic Oncology
      외국어명 : Korean Journal of Gynecologic Oncology -> Journal of Gynecologic Oncology
      KCI등재후보
      2008-01-01 평가 등재후보 1차 FAIL (등재후보1차) KCI등재후보
      2007-01-01 평가 등재후보학술지 유지 (등재후보1차) KCI등재후보
      2006-09-13 학술지명변경 한글명 : 대한부인종양.콜포스코피학회지 -> 부인종양
      외국어명 : 미등록 -> Korean Journal of Gynecologic Oncology
      KCI등재후보
      2005-01-01 평가 등재후보학술지 선정 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 2.18 0.12 1.48
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      1.13 0.9 0.732 0
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼